TROP2靶向抗体偶联药物在晚期非小细胞肺癌治疗中的研究进展

doi:10.3760/cma.j.cn371439-20251223-00080

摘要/Abstract

摘要：

肺癌是全球癌症相关死亡的主要原因之一。非小细胞肺癌（NSCLC）患者在经历一线免疫或靶向治疗耐药后，后续治疗选择有限。人滋养层细胞表面抗原2（TROP2）在NSCLC中广泛表达，并与肿瘤侵袭性增强及不良预后密切相关，已成为抗体偶联药物（ADC）的重要治疗靶点。TROP2-ADC在既往接受化疗、免疫治疗或靶向治疗后进展的晚期NSCLC患者中显示出一定疗效，同时联合免疫治疗、靶向治疗等策略亦展现出潜在的协同作用。深入探究TROP2-ADC的作用机制及相关临床研究进展可为后线治疗策略的优化及未来研究方向提供参考。

关键词: 癌, 非小细胞肺, 人滋养层细胞表面抗原2, 抗体偶联药物

Abstract:

Lung cancer remains a leading cause of global cancer mortality. Subsequent treatment options are limited for patients with non-small cell lung cancer （NSCLC） resistant to first-line immunotherapy or targeted therapy. Trophoblast cell-surface antigen 2 （TROP2）， widely expressed in NSCLC and associated with enhanced tumor invasiveness and poor prognosis， has emerged as a key target for antibody-drug conjugates （ADCs）. TROP2-ADCs have demonstrated certain efficacy in advanced NSCLC patients who have progressed after chemotherapy， immunotherapy， or targeted therapy， while combination strategies also show potential synergy. A thorough exploration of the mechanism of action of TROP2-ADC and related clinical research progress can provide references for the optimization of second-line treatment strategies and the direction of future research.

Key words: Carcinoma, non-small-cell lung, Trophoblast cell-surface antigen 2, Antibody-drug conjugates

乔丹, 聂磊, 张一力, 刘佳, 陈文娟. TROP2靶向抗体偶联药物在晚期非小细胞肺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2026, 53(8): 496-501.

Qiao Dan, Nie Lei, Zhang Yili, Liu Jia, Chen Wenjuan. Research progress of TROP2-targeted antibody-drug conjugates for the treatment of advanced non-small cell lung cancer[J]. Journal of International Oncology, 2026, 53(8): 496-501.

参考文献 54

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	Kuo P, Elboudwarej E, Zavodovskaya M, et al. Trop-2 expression in non-small cell lung cancer[J]. PLoS One, 2025, 20(4): e0321555. DOI: 10.1371/journal.pone.0321555.
[3]	Liu XL, Ma LN, Li JYX, et al. Trop2-targeted therapies in solid tumors: advances and future directions[J]. Theranostics, 2024, 14(9): 3674-3692. DOI: 10.7150/thno.98178. pmid: 38948057
[4]	Yang CJ, Chuang CH, Chen YW, et al. The complex interplay of TROP2 and PD-L1 in immune regulation and drug resistance in lung cancer[J]. Am J Cancer Res, 2025, 15(5): 2413-2426. DOI: 10.62347/NHFJ1535.
[5]	Zheng WP, Huang FY, Dai S, et al. Toxicarioside O inhibits cell proliferation and epithelial-mesenchymal transition by downregulation of Trop2 in lung cancer cells[J]. Front Oncol, 2021, 10: 609275. DOI: 10.3389/fonc.2020.609275.
[6]	Pommier Y, Nussenzweig A, Takeda S, et al. Human topoisomerases and their roles in genome stability and organization[J]. Nat Rev Mol Cell Biol, 2022, 23(6): 407-427. DOI: 10.1038/s41580-022-00452-3.
[7]	Wang RL, Hu BH, Pan ZY, et al. Antibody-drug conjugates (ADCs): current and future biopharmaceuticals[J]. J Hematol Oncol, 2025, 18: 51. DOI: 10.1186/s13045-025-01704-3.
[8]	Santin NG, Sethi N, Bellone S, et al. Preclinical activity of datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate targeting TROP2, in poorly differentiated endometrial carcinomas[J]. Cancer Res Commun, 2025, 5(9): 1611-1620. DOI: 10.1158/2767-9764.CRC-25-0251.
[9]	Inamura K, Yokouchi Y, Kobayashi M, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes[J]. Oncotarget, 2017, 8(17): 28725-28735. DOI: 10.18632/oncotarget.15647. pmid: 28404926
[10]	Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)[J]. Oncotarget, 2015, 6(26): 22496-22512. DOI: 10.18632/oncotarget.4318. pmid: 26101915
[11]	Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541. DOI: 10.1056/NEJMoa2028485.
[12]	Wahby S, Fashoyin-Aje L, Osgood CL, et al. FDA Approval Summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer[J]. Clin Cancer Res, 2021, 27(7): 1850-1854. DOI: 10.1158/1078-0432.CCR-20-3119.
[13]	国家药品监督管理局. 2022年06月10日药品批准证明文件待领取信息发布[EB/OL]. (2022-06-10)[2026-06-04]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220610083017154.html.
[14]	Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase Ⅲ EVOKE-01 study[J]. J Clin Oncol, 2024, 42(24): 2860-2872. DOI: 10.1200/JCO.24.00733.
[15]	Cheng YZ, Yuan XX, Tian Q, et al. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132[J]. Front Oncol, 2022, 12: 951589. DOI: 10.3389/fonc.2022.951589.
[16]	Patel SP, Gadgeel S, Mino-Kenudson M, et al. Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer[J]. Cancer Treat Rev, 2026, 143: 103050. DOI: 10.1016/j.ctrv.2025.103050.
[17]	Zhao S, Cheng Y, Wang Q, et al. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials[J]. Nat Med, 2025, 31(6): 1976-1986. DOI: 10.1038/s41591-025-03638-2.
[18]	Fang WF, Li XY, Wang QM, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open-label, randomised controlled trial[J]. BMJ, 2025, 389: e085680. DOI: 10.1136/bmj-2025-085680.
[19]	国家药品监督管理局. 2025年03月10日药品批准证明文件送达信息[EB/OL]. (2025-03-10)[2026-06-04]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20250310135234153.html.
[20]	四川科伦博泰生物医药股份有限公司. 注射用芦康沙妥珠单抗说明书[EB/OL]. (2025-03-26)[2026-06-04]. https://www.kelun-biotech.com/upload/2025-03-26/2613344727.pdf.
[21]	Fang WF, Wu L, Meng XJ, et al. Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC[J]. N Engl J Med, 2026, 394(1): 13-26. DOI: 10.1056/NEJMoa2512071.
[22]	Zhang L, Fang WF, Cheng Y, et al. Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: preliminary results from a phase 2 study[J]. J Clin Oncol, 2025, 43(16_suppl): 8615. DOI: 10.1200/JCO.2025.43.16_suppl.8615.
[23]	Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells[J]. Mol Cancer Ther, 2021, 20(12): 2329-2340. DOI: 10.1158/1535-7163.MCT-21-0206.
[24]	McNamara B, Greenman M, Bellone S, et al. Preclinical activity of datopotamab deruxtecan, a novel TROP 2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma[J]. Gynecol Oncol, 2024, 189: 16-23. DOI: 10.1016/j.ygyno.2024.07.002. pmid: 38981151
[25]	Shimizu T, Sands J, Yoh K, et al. First-in-human, phase Ⅰ dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01[J]. J Clin Oncol, 2023, 41(29): 4678-4687. DOI: 10.1200/JCO.23.00059.
[26]	Sands J, Ahn MJ, Lisberg A, et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase Ⅱ TROPION-Lung05 study[J]. J Clin Oncol, 2025, 43(10): 1254-1265. DOI: 10.1200/JCO-24-01349.
[27]	Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase Ⅲ TROPION-Lung01 study[J]. J Clin Oncol, 2025, 43(3): 260-272. DOI: 10.1200/JCO-24-01544.
[28]	Forveille S, Leduc M, Sauvat A, et al. Datopotamab deruxtecan induces hallmarks of immunogenic cell death[J]. Cell Stress, 2025, 9: 194-200. DOI: 10.15698/cst2025.08.311. pmid: 40800161
[29]	Oh K, Nam A, Bang J, et al. Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells[J]. Cell Commun Signal, 2024, 22(1): 518. DOI: 10.1186/s12964-024-01893-3.
[30]	Reck M, Patel JD, Gray JE, et al. First-line sacituzumab govitecan plus pembrolizumab in metastatic NSCLC: PD-L1 TPS <50% and ≥50% cohorts of the EVOKE-02 study[J]. J Thorac Oncol, 2026, 21(3): 103509. DOI: 10.1016/j.jtho.2025.10.016.
[31]	ClinicalTrials. Gov. Study of pembrolizumab (MK-3475) monotherapy versus sacituzumab govitecan in combination with pembrolizumab for participants with metastatic non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥50% (MK-3475-D46) (EVOKE-03)[EB/OL]. (2025-12-15)[2025-12-16]. https://clinicaltrials.gov/study/NCT05609968.
[32]	Hong SD, Wang QM, Cheng Y, et al. First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial[J]. Nat Med, 2025, 31(11): 3654-3661. DOI: 10.1038/s41591-025-03883-5.
[33]	ClinicalTrials. Gov. Sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab versus pembrolizumab alone in metastatic NSCLC with PD-L1 TPS ≥50% (MK-2870-007) (TroFuse-007)[EB/OL]. (2025-12-11)[2025-12-16]. https://clinicaltrials.gov/study/NCT06170788.
[34]	ClinicalTrials. Gov. A study of SKB264 in combination with pembrolizumab versus pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer[EB/OL]. (2025-12-08)[2025-12-16]. https://clinicaltrials.gov/study/NCT06448312.
[35]	ClinicalTrials. Gov. Pembrolizumab with or without maintenance sacituzumab tirumotecan (Sac-TMT; MK-2870) in metastatic squamous non-small cell lung cancer (NSCLC) (MK-2870-023)[EB/OL]. (2025-12-11)[2025-12-16]. https://clinicaltrials.gov/study/NCT06422143.
[36]	ClinicalTrials. Gov. A study of SKB264 in combination with pembrolizumab versus chemotherapy in combination with pembrolizumab as first-line treatment for PD-L1 negative patients with locally advanced or metastatic non-squamous non-small cell lung cancer[EB/OL]. (2025-12-15)[2025-12-16]. https://clinicaltrials.gov/study/NCT06711900.
[37]	Levy BP, Paz-Ares LG, Lin C, et al. TROPION-Lung02: datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC)[J]. J Clin Oncol, 2025, 43(16_suppl): 8501. DOI: 10.1200/JCO.2025.43.16_suppl.8501.
[38]	Cuppens K, Papadopoulos K, Nishio M, et al. 8O: First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): results from TROPION-Lung04 (cohorts 2 and 4)[J]. ESMO Open, 2025, 10(Suppl 2): 104164. DOI: 10.1016/j.esmoop.2025.104164.
[39]	ClinicalTrials. Gov. Datopotamab deruxtecan (Dato-DXd) and pembrolizumab with or without platinum chemotherapy in 1L non-small cell lung cancer (TROPION-Lung07)[EB/OL]. (2025-09-11)[2025-12-16]. https://clinicaltrials.gov/study/NCT05555732.
[40]	ClinicalTrials. Gov. Study of Dato-DXd plus pembrolizumab vs pembrolizumab alone in the first-line treatment of subjects with advanced or metastatic NSCLC without actionable genomic alterations[EB/OL]. (2025-08-27)[2025-12-16]. https://clinicaltrials.gov/study/NCT05215340.
[41]	ClinicalTrials. Gov. Phase Ⅲ, open-label, study of first-line Dato-DXd in combination with rilvegostomig for advanced non-squamous NSCLC with high PD-L1 expression (TC ≥50%) and without actionable genomic alterations (TROPION-Lung10)[EB/OL]. (2025-10-27)[2025-12-16]. https://clinicaltrials.gov/study/NCT06357533.
[42]	Zhou Q, Zhao H, Lu S, et al. Consensus on the lung cancer management after third-generation EGFR-TKI resistance[J]. Lancet Reg Health West Pac, 2024, 53: 101260. DOI: 10.1016/j.lanwpc.2024.101260.
[43]	Wang R, Chen YH, Li LP, et al. Osimertinib acquired resistance among patients with EGFR-mutated NSCLC: from molecular mechanisms to clinical therapeutic strategies[J]. Cancer Drug Resist, 2025, 8: 61. DOI: 10.20517/cdr.2025.140.
[44]	Le X, Hendriks L, Morabito A, et al. 1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD[J]. J Thorac Oncol, 2025, 20(3_suppl): S2-S4. DOI: 10.1016/S1556-0864(25)00196-0.
[45]	ClinicalTrials. Gov. Phase Ⅲ, open-label study of first-line osimertinib with or without datopotamab deruxtecan for EGFR-mutated locally advanced or metastatic non-small cell lung cancer (TROPION-Lung 14)[EB/OL]. (2025-11-17)[2025-12-16]. https://clinicaltrials.gov/study/NCT06350097.
[46]	ClinicalTrials. Gov. A study to investigate the efficacy and safety of Dato-DXd with or without osimertinib compared with platinum-based doublet chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (TROPION-Lung 15)[EB/OL]. (2025-12-03)[2025-12-16]. https://clinicaltrials.gov/study/NCT06417814.
[47]	Choi Y, Jung K. Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy[J]. Exp Mol Med, 2023, 55(11): 2308-2319. DOI: 10.1038/s12276-023-01114-w. pmid: 37907742
[48]	ClinicalTrials. Gov. Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab in 3rd generation EGFR-TKI-treated advanced EGFR-mutant nonsquamous NSCLC with brain metastasis[EB/OL]. (2025-09-29)[2025-12-16]. https://clinicaltrials.gov/study/NCT07197008.
[49]	Aleksandrov R, Hristova R, Stoynov S, et al. The chromatin response to double-strand DNA breaks and their repair[J]. Cells, 2020, 9(8): 1853. DOI: 10.3390/cells9081853.
[50]	ClinicalTrials. Gov. A study of valemetostat tosylate in combination with DXd ADCs in subjects with solid tumors[EB/OL]. (2025-10-09)[2025-12-16]. https://clinicaltrials.gov/study/NCT06244485.
[51]	Coates JT, Sun S, Leshchiner I, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer[J]. Cancer Discov, 2021, 11(10): 2436-2445. DOI: 10.1158/2159-8290.CD-21-0702. pmid: 34404686
[52]	Brea EJ, Baldacci S, Savage N, et al. Systematic engineering of TROP2-targeted CAR T-cell therapy overcomes resistance pathways in solid tumors[J]. Cancer Immunol Res, 2025, 13(11): 1749-1763. DOI: 10.1158/2326-6066.CIR-25-0527.
[53]	Scattolin D, Maso AD, Ferro A, et al. The emerging role of schlafen-11 (SLFN11) in predicting response to anticancer treatments: focus on small cell lung cancer[J]. Cancer Treat Rev, 2024, 128: 102768. DOI: 10.1016/j.ctrv.2024.102768.
[54]	Khoury R, Saleh K, Khalife N, et al. Mechanisms of resistance to antibody-drug conjugates[J]. Int J Mol Sci, 2023, 24(11): 9674. DOI: 10.3390/ijms24119674.